Saxonov Serge 4
4 · 10x Genomics, Inc. · Filed Jun 24, 2026
Research Summary
AI-generated summary of this filing
10x Genomics (TXG) CEO Serge Saxonov Sells Shares
What Happened
- Serge Saxonov, CEO of 10x Genomics (TXG), sold a total of 30,000 shares in open-market transactions on June 22, 2026, generating approximately $1,033,267 in proceeds.
- The sales were executed in four tranches: 8,527 shares at a weighted avg $33.29 ($283,855); 9,991 shares at $34.28 ($342,506); 9,821 shares at $35.32 ($346,837); and 1,661 shares at $36.16 ($60,069). All transactions are coded as S (sale).
Key Details
- Transaction date: June 22, 2026; Form 4 filed June 24, 2026 (filed within typical two-business-day window).
- Prices: Weighted average prices reported above; individual trades were executed in multiple fills with ranges of $32.75–$33.74, $33.76–$34.71, $34.86–$35.82, and $35.98–$36.24 (per footnotes).
- Ownership after transaction: Not provided in the supplied excerpt of the filing.
- Notable footnotes: Sales were made pursuant to a pre-established Rule 10b5-1 trading plan adopted Nov 29, 2025 (F1). Several holdings referenced in the filing are held in trusts (Andromeda Trust, Y/S Descendants' Trust, Y/S Pot Trust) for which Saxonov serves as trustee (F6–F8).
- Transaction code: S = Sale.
Context
- Sales done under a 10b5-1 plan are prearranged and generally indicate scheduled/automated selling rather than an immediate change in the insider’s view; they are common and do not necessarily signal negative sentiment.
- For retail investors, purchases by insiders often carry more informational weight than routine plan-based sales; this filing documents a routine monetization of shares rather than an acquisition.
Insider Transaction Report
Form 4
Saxonov Serge
DirectorChief Executive Officer
Transactions
- Sale
Class A Common Stock
[F1][F2]2026-06-22$33.29/sh−8,527$283,855→ 1,129,853 total - Sale
Class A Common Stock
[F1][F3]2026-06-22$34.28/sh−9,991$342,506→ 1,119,862 total - Sale
Class A Common Stock
[F1][F4]2026-06-22$35.32/sh−9,821$346,837→ 1,110,041 total - Sale
Class A Common Stock
[F1][F5]2026-06-22$36.16/sh−1,661$60,069→ 1,108,380 total
Holdings
- 27(indirect: See footnote)
Class A Common Stock
[F6] - 213,250(indirect: See footnote)
Class A Common Stock
[F7] - 71,644(indirect: See footnote)
Class A Common Stock
[F8]
Footnotes (8)
- [F1]The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $32.75 to $33.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]This transaction was executed in multiple trades at prices ranging from $33.76 to $34.71, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F4]This transaction was executed in multiple trades at prices ranging from $34.86 to $35.82, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F5]This transaction was executed in multiple trades at prices ranging from $35.98 to $36.24, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F6]The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
- [F7]The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
- [F8]The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
Signature
/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov|2026-06-24